Does Rebif Cause Skin Necrosis?
Rebif (interferon beta-1a) can cause severe injection-site reactions, including rare cases of skin necrosis. This manifests as localized death of skin tissue at the injection site, often after prolonged use or improper technique. Clinical reports and post-marketing data document instances of necrosis, ulceration, or cellulitis requiring surgical debridement.[1][2]
How Common Are These Reactions?
Skin necrosis occurs infrequently, affecting less than 1% of patients in trials, but real-world surveillance shows higher rates with subcutaneous injections. Reactions typically appear as redness, swelling, or pain escalating to necrosis within weeks to months. Women and those with prior skin sensitivity report more cases.[1][3]
What Do Patients Describe?
Users on forums and FDA adverse event reports note blue-black lesions, open wounds, or scarring at injection sites, sometimes lasting months and needing antibiotics or excision. Healing can take 2-6 months after stopping Rebif.[2][4]
Why Does It Happen?
Necrosis links to local inflammation from interferon beta irritating tissue, compounded by repeated injections in the same area or subcutaneous leakage. Risk rises with higher doses (44 mcg) or poor rotation of sites like abdomen or thighs.[1][3]
How to Prevent It?
Rotate injection sites weekly, use proper technique (perpendicular insertion, no rubbing), and monitor for early signs like persistent redness. Guidelines recommend pausing treatment if severe reactions emerge.[1][5]
What If Necrosis Develops?
Seek immediate medical care—debridement or wound care may be needed. Most cases resolve without long-term issues, but scarring occurs. Report to FDA MedWatch for tracking.[2][4]
Alternatives for MS Patients Worried About Skin Reactions?
Switch to oral options like fingolimod or teriflunomide, or other injectables like glatiramer acetate (less necrosis risk). Discuss with neurologists based on MS type and history.[3][5]
Sources
[1]: Rebif Prescribing Information (EMD Serono)
[2]: FDA Adverse Event Reporting System (FAERS) data on Rebif
[3]: PubMed: Injection-site reactions with interferon beta
[4]: Drugs.com user reviews and side effects
[5]: National MS Society guidelines on disease-modifying therapies